RT Journal Article
SR Electronic
T1 Chronotype changes after sex hormone use: a prospective cohort study in transgender users of gender-affirming hormones
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.15.23291434
DO 10.1101/2023.06.15.23291434
A1 Morssinkhof, Margot W. L.
A1 Zwager, Annefleur
A1 Tuuk, Karin van der
A1 Heijer, Martin den
A1 van der Werf, Ysbrand D.
A1 Stenvers, Dirk Jan
A1 Broekman, Birit F. P.
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.15.23291434.abstract
AB Background Chronotype, an individual’s preferred sleep-wake timing, is influenced by sex and age. Men report a later chronotype than women and age is associated with earlier chronotype. The sex-related changes in chronotype coincide with puberty and menopause. However, the effects of sex hormones on human chronotype remain unclear.Aim To examine the impact of 3 months of gender-affirming hormone therapy (GAHT) on chronotype in transgender persons.Methods This study used data from 93 participants from the prospective RESTED cohort, including 49 transmasculine (TM) participants starting testosterone and 44 transfeminine (TF) participants starting estrogens and antiandrogens. Midpoint of sleep and sleep duration were measured using the ultra-short Munich ChronoType Questionnaire (µMCTQ).Results After 3 months of GAHT, TM participants’ midpoint of sleep increased by 24 minutes (95%CI: 3 to 45), whereas TF participants’ midpoint of sleep decreased by 21 minutes (95%CI: −38 to −4). Total sleep duration did not change significantly in either group.Conclusion This study provides the first prospective assessment of sex hormone use and chronotype in transgender persons, showing that GAHT can change chronotype in line with cisgender sex differences. These findings provide a basis for future studies on biological mechanisms and clinical consequences of chronotype changes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the NWO, Netherlands [Veni grant, grant number 91619085, 2018] supplied to BB. The NWO had no involvement in the study design, data collection, analysis or interpretation of the data, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The RESTED study was classified as a non-WMO study by the Medical Ethical Committee of the Amsterdam University Medical Centers (location VUmc) and the local committee at the University Medical Center Groningen, meaning that the Medical Research Involving Human Subjects Act (WHO) did not apply to the data collection of this study (study id. 2019.353).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData of the present study are available upon reasonable request.